Evidence map›Paper›PMID 19404616›Full record

ArticlePsychopharmacology2009

Dissociable effects of noradrenaline, dopamine, and serotonin uptake blockade on stop task performance in rats.

Andrea Bari, Dawn M Eagle, Adam C Mar, Emma S J Robinson, Trevor W Robbins

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychopharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 193 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Review
  13. Research progress of tDCS in the treatment of ADHD.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
  14. Article
  15. Article
  16. Locus Coeruleus Integrity Is Linked to Response Inhibition Deficits in Parkinson's Disease and Progressive Supranuclear Palsy.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Andrea BariDepartment of Experimental Psychology and Behavioural and Clinical Neuroscience Institute, University of Cambridge, Downing Street, Cambridge CB23EB, UK.
Dawn M Eagle
Adam C Mar
Emma S J Robinson
Trevor W Robbins
University of Cambridge · GBUniversity of Bristol · GB

Funding

Medical Research Council G0001354Wellcome TrustWellcome Trust 076274/z/04/z
6 · The paper itself

Abstract

rationaleThe stop-signal paradigm measures the ability to stop a motor response after its execution has been initiated. Impairments in inhibiting inappropriate behavior and prolonged stop-signal reaction times (SSRTs) are characteristic of several psychiatric disorders, most notably attention deficit/hyperactivity disorder. While there is relative consensus regarding the anatomical substrates of behavioral inhibition, the neurochemical imbalance responsible for the deficits in stopping displayed by impulsive individuals is still a matter of debate.

objectiveThe aim of this study was to investigate the effects of manipulating brain monoamine levels on stop task parameters.

methodsLister-hooded rats were trained on the rodent version of the stop-signal task and administered different monoamine transporter inhibitors: citalopram, which selectively blocks the serotonin transporter; atomoxetine, which selectively blocks the noradrenaline transporter; and GBR-12909, which selectively blocks the dopamine transporter (DAT), and the alpha-2 adrenergic agonist guanfacine.

resultsAtomoxetine speeded SSRT and increased accuracy for go-trials. Citalopram slowed go reaction time and decreased go accuracy at the highest dose (1 mg/kg). GBR-12909 speeded go reaction time and impaired both go and stop accuracy. Guanfacine negatively modulated all principal stop and go measures at the highest dose used (0.3 mg/kg).

conclusionsThe results suggest that atomoxetine exerts its beneficial effects on SSRT via its action on noradrenaline re-uptake, as the specific DAT blocker GBR-12909 and serotonin reuptake blockade had only minor effects on SSRT. The speeding of the go reaction time by dopamine reuptake blockade is consistent with the hypothesis that the hypothetical stop and go processes are modulated by distinct monoaminergic systems.

Indexed as

Inhibition, PsychologicalAnalysis of VarianceAnimalsAtomoxetine HydrochlorideBehavior, AnimalCitalopramConditioning, OperantDopamineDose-Response Relationship, DrugGuanfacineMaleNeurotransmitter Uptake InhibitorsNorepinephrinePiperazinesPropylaminesRatsAtomoxetine HydrochlorideCitalopramDopamineGuanfacineNeurotransmitter Uptake InhibitorsNorepinephrinePiperazinesPropylaminesSelective Serotonin Reuptake InhibitorsSerotoninvanoxerine

Identifiers

PMID19404616
PMCPMC2705723
OpenAlexW2130491227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.